Company Profiles

driven by the PitchBook Platform

Atlas Genetics

Atlas Genetics
2005 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series D LATEST DEAL TYPE
$35M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of a novel molecular diagnostic system is designed for decentralised laboratory, point-of-care and other near-patient settings. The company's molecular diagnostic system is based on a patent- protected electrochemical sensor is used for the ultra-rapid diagnosis of a broad range of infectious diseases such as chlamydia, gonorrhoea, meningitis and MRSA enabling physicians to get accurate diagnostic reports.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Drug Discovery
Primary Office
  • Derby Court, Epsom Square
  • White Horse Business Park, Wiltshire
  • Trowbridge BA14 0XG
  • England

+44 01225 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Atlas Genetics’s full profile, request a free trial.

Atlas Genetics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series D) 23-Jan-2017 $35M 000.00 00000 Completed Generating Revenue
9. Grant 15-Mar-2016 000.00 Completed Generating Revenue
8. Later Stage VC (Series C) 29-Jan-2015 000.00 000.00 000.00 Completed Generating Revenue
7. Later Stage VC (Series B) 29-Apr-2014 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 28-Feb-2011 00.00 00.000 Completed Generating Revenue
5. Early Stage VC 30-Sep-2009 00000 00.000 Completed Startup
4. Grant 00000 00.000 Completed Startup
3. Early Stage VC 18-Feb-2008 00.000 00.000 Completed Startup
2. Early Stage VC 09-Aug-2006 $946K $946K Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Atlas Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series C 00,000 00.000000 00 0000.0 0000.0 00 0000.0 00.000
Series B4 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series B3 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series B2 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Series B1 00,000 00.000000 00.00 00.00 00 00.00 0.000
Series A2 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Series A1 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
EIS 3 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
EIS 2 577 $0.012334 $123.34 $123.34 1x $123.34 0.12%
EIS 1 1,411 $0.012334 $111.74 $111.74 1x $111.74 0.3%
To view this company’s complete Cap Table, request access »

Atlas Genetics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Wondfo Corporation Minority 000 0000 000000 0
Innovate UK Accelerator/Incubator 000 0000 000000 0
Wellcome Trust Limited Partner 000 0000 000000 0
RMI Partners Venture Capital Minority 000 0000 000000 0
BB Biotech Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Atlas Genetics Executive Team (12)

Name Title Board
Seat
Contact
Info
Ben Arlett Chief Technology Officer
John Clarkson Ph.D Chief Executive Officer & Board Member
Marc Jones Chief Financial Officer & Chief Operating Officer
Lee Johnston Jr. Chief Financial Officer
Karen Yates Director, Finance & Board Member

2 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Atlas Genetics Board Members (13)

Name Representing Role Since Contact
Info
Christopher Price Atlas Genetics Board Member 000 0000
Clive Davis Self Board Observer 000 0000
Florent Gros Novartis Venture Fund Board Member 000 0000
Joachim Rothe Ph.D Life Sciences Partners Board Member 000 0000
John Clarkson Ph.D Atlas Genetics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »